# US 2025/0154283 A1 · Methods of treating blood disorders with vwf-targeted monospecific antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154283 A1
- Document ID: US20250154283A1
- Status: Published application
- Kind: A1
- Application number: 18/838,515
- Filed: 2023-02-14
- Published: 2025-05-15
- Earliest claimed: 2022-02-15
- Assignees: Hemab ApS
- Applicants: Hemab ApS
- Inventors: Henrik Østergaard; Prafull S. Gandhi; Johan H. Faber; Catherine Rea; Benny Sørensen
- Web page: https://patentgrep.com/patent/US20250154283A1

## CPC

- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 16/36: against blood coagulation factors
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are antibodies that bind to von Willebrand factor to an epitope positioned at a cysteine knot (CK) domain. Such antibodies are useful for methods of treatment, such methods of treating one or more blood disorders characterized by excessive bleeding.

## Claims

### Claim 1

A monospecific antibody comprising an antigen-binding site that specifically binds to an epitope of a von Willebrand Factor (VWF) protein positioned at a cysteine knot (CK) domain and a fragment crystallizable (Fc) region, wherein binding of the antibody to the VWF protein in blood plasma results in accumulation of the VWF protein in blood plasma as compared to a blood plasma level of the VWF protein in the absence of the antibody.

### Claim 2 (depends on 1)

The monospecific antibody of claim 1, wherein the antibody is a monovalent antibody.

### Claim 3 (depends on 1, 2)

The monospecific antibody of claim 1 or 2, wherein the Fc region is a wild-type Fc region.

### Claim 4 (depends on 1, 2)

The monospecific antibody of claim 1 or 2, wherein the Fc region is a modified Fc region.

### Claim 5 (depends on 4)

The monospecific antibody of claim 4, wherein the modified Fc region comprises one or more mutations selected from the group consisting of a R435H mutation, N434A mutation, T252L/T253S/T254F mutation, E294delta/T307P/N434Y mutation, T256N/A378V/S383N/N434Y mutation, E294 delta mutation, M252Y/S254T/T256E mutation, M428L/N434S mutation, T307A/E380A/N434A mutation, T250Q/M428L mutation, T250Q/M428F mutation, T250E/M428F mutation, T250E/M428L mutation, T256D/Q311V/A378V mutation, T256D/H286D/T307R/Q311V/A378V mutation, H285N/T307Q/N315D mutation, T307Q/Q311V/A378V mutation, H285D/T307Q/A378V mutation, L234F/L235E/P331S mutation, L234F/L235Q/K322Q mutation, L234F/L235Q/P331G mutation, L234F/L235A/K322Q mutation, S228P/F234A/L235A/G237A/P238S mutation, L234A/L235E/G237A/A330S/P331S mutation, F243A/V264A mutation, S228P/L235E/P329G mutation, M252Y/M428L mutation, D2591/V308F mutation, T307Q/N434S mutation, M428L/V308F mutation, Q311V/N434S mutation, H433K/N434F mutation, E258F/V427T mutation, K288E/H435K mutation, F234A/L235A mutation, F234A/L235A/S228P mutation, L234A/L235A/P329G mutation, F234A/L235A/P329G mutation, P329G mutation, F234 mutation, S228P mutation, delta-K447 mutation, L235A mutation, L235E mutation, V308P mutation, V308W mutation, V308Y mutation, V308F mutation, N434S mutation, T307 mutation, Q312A mutation, K322A mutation, P329A mutation, P331A mutation, P238A mutation, D265A mutation, D269A mutation, D270A mutation, N297A mutation, A327Q mutation, P329A mutation, S239A mutation, E294A mutation, Q295A mutation, V303A mutation, A330R mutation, T299A mutation, F234A mutation, T366W mutation, T366S mutation, L368A mutation, Y407V mutation, F405L mutation, K409R mutation, F405L/R409K mutation, and any combination thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The monospecific antibody of any one of claims 1-5, wherein the modified Fc region is N-terminally truncated.

### Claim 7 (depends on 6)

The monospecific antibody of claim 6, wherein the modified Fc region is N-terminally truncated by 1, 2, 3, 4, 5, 6, 7, 8, 9 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or more amino acid residues.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The monospecific antibody of any one of claims 1-7, wherein the antibody is a human IgG4 antibody comprising a first heavy chain and a second heavy chain.

### Claim 9 (depends on 8)

The monospecific antibody of claim 8, wherein the first heavy chain comprises a S228P/T366W/F234A/L235A/delta-K447 mutation and the second heavy chain comprises a S228P/T366S/L368A/Y407V/F234A/L235A/delta-K447 mutation.

### Claim 10 (depends on 8)

The monospecific antibody of claim 8, wherein the first heavy chain comprises a S228P/T366W/delta-K447 mutation and the second heavy chain comprises a S228P/T366S/L368A/Y407V/delta-K447 mutation.

### Claim 11 (depends on 9, 10)

The monospecific antibody of claim 9 or 10, wherein the first heavy chain and the second heavy chain further comprise a M252Y/S254T/T256E mutation.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 16.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The monospecific antibody of any one of claims 1-12, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 16.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The monospecific antibody of any one of claims 1-13, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 16.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The monospecific antibody of any one of claims 1-14, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 16.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The monospecific antibody of any one of claims 1-15, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 12 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 16.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The monospecific antibody of any one of claims 1-16, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 18.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The monospecific antibody of any one of claims 1-17, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 12 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 16 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 18.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The monospecific antibody of any one of claims 1-18, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 453, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 473, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 463.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 23.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 20)

The monospecific antibody of any one of claims 1-11 and 20, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 23.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 20)

The monospecific antibody of any one of claims 1-11, 20, and 21, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 23.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 20, 21, 22)

The monospecific antibody of any one of claims 1-11 and 20-22, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 23.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 20, 21, 22, 23)

The monospecific antibody of any one of claims 1-11 and 20-23, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 19 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 23.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 20, 21, 22, 23, 24)

The monospecific antibody of any one of claims 1-11 and 20-24, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 25.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 20, 21, 22, 23, 24, 25)

The monospecific antibody of any one of claims 1-11 and 20-25, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 19 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 23 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 25.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 20, 21, 22, 23, 24, 25, 26)

The monospecific antibody of any one of claims 1-11 and 20-26, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 454, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 474, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 464.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 30.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 28)

The monospecific antibody of any one of claims 1-11 and 28, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 30.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 28)

The monospecific antibody of any one of claims 1-11, 28, and 29 wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 30.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 28, 29, 30)

The monospecific antibody of any one of claims 1-11 and 28-30, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 30.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 28, 29, 30, 31)

The monospecific antibody of any one of claims 1-11 and 28-31, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 26 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 30.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 28, 29, 30, 31, 32)

The monospecific antibody of any one of claims 1-11 and 28-32, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 29; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 32.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 28, 29, 30, 31, 32, 33)

The monospecific antibody of any one of claims 1-11 and 28-33, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 26 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 29; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 30 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 32.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 37.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 35)

The monospecific antibody of any one of claims 1-11 and 35, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 37.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 35)

The monospecific antibody of any one of claims 1-11, 35, and 36, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 37.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 35, 36, 37)

The monospecific antibody of any one of claims 1-11 and 35-37, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 37.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 35, 36, 37, 38)

The monospecific antibody of any one of claims 1-11 and 35-38, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 33 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 37.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 35, 36, 37, 38, 39)

The monospecific antibody of any one of claims 1-11 and 35-39, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 36; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 39.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 35, 36, 37, 38, 39, 40)

The monospecific antibody of any one of claims 1-11 and 35-40, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 33 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 36; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 37 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 39.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 35, 36, 37, 38, 39, 40, 41)

The monospecific antibody of any one of claims 1-11 and 35-41, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 455, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 475, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 465.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 44.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 43)

The monospecific antibody of any one of claims 1-11 and 43, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 44.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 43)

The monospecific antibody of any one of claims 1-11, 43, and 44, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 44.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 43, 44, 45)

The monospecific antibody of any one of claims 1-11 and 43-45, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 44.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 43, 44, 45, 46)

The monospecific antibody of any one of claims 1-11 and 43-46, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 40 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 44.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 43, 44, 45, 46, 47)

The monospecific antibody of any one of claims 1-11 and 43-47, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 43; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 46.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 43, 44, 45, 46, 47, 48)

The monospecific antibody of any one of claims 1-11 and 43-48, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 40 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 43; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 44 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 46.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 43, 44, 45, 46, 47, 48, 49)

The monospecific antibody of any one of claims 1-11 and 43-49, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 456, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 476, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 466.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 51.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 51)

The monospecific antibody of any one of claims 1-11 and 51, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 51.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 51)

The monospecific antibody of any one of claims 1-11, 51, and 52, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 51.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 51, 52, 53)

The monospecific antibody of any one of claims 1-11 and 51-53, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 51.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 51, 52, 53, 54)

The monospecific antibody of any one of claims 1-11 and 51-54, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 47 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 51.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 51, 52, 53, 54, 55)

The monospecific antibody of any one of claims 1-11 and 51-55, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 50; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 52, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 53.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 51, 52, 53, 54, 55, 56)

The monospecific antibody of any one of claims 1-11 and 51-56, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 47 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 50; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 51 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 52, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 53.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 58.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 58)

The monospecific antibody of any one of claims 1-11 and 58, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 58.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 58)

The monospecific antibody of any one of claims 1-11, 58, and 59, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 58.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 58, 59, 60)

The monospecific antibody of any one of claims 1-11 and 58-60, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 58.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 58, 59, 60, 61)

The monospecific antibody of any one of claims 1-11 and 58-61, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 54 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 58.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 58, 59, 60, 61, 62)

The monospecific antibody of any one of claims 1-11 and 58-62, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 57; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 60.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 58, 59, 60, 61, 62, 63)

The monospecific antibody of any one of claims 1-11 and 58-63, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 54 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 57; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 58 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 60.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 58, 59, 60, 61, 62, 63, 64)

The monospecific antibody of any one of claims 1-11 and 58-64, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 457, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 577, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 567.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 65.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 66)

The monospecific antibody of any one of claims 1-11 and 66, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 65.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 66)

The monospecific antibody of any one of claims 1-11, 66, and 67, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 65.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 66, 67, 68)

The monospecific antibody of any one of claims 1-11 and 66-68, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 65.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 66, 67, 68, 69)

The monospecific antibody of any one of claims 1-11 and 66-69, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 65.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 66, 67, 68, 69, 70)

The monospecific antibody of any one of claims 1-11 and 66-70, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 67.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 66, 67, 68, 69, 70, 71)

The monospecific antibody of any one of claims 1-11 and 66-71, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 65 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 67.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 65.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 73)

The monospecific antibody of any one of claims 1-11 and 73, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 65.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 73)

The monospecific antibody of any one of claims 1-11, 73, and 74, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 65.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 73, 74, 75)

The monospecific antibody of any one of claims 1-11 and 73-75, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 65.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 73, 74, 75, 76)

The monospecific antibody of any one of claims 1-11 and 73-76, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 65.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 73, 74, 75, 76, 77)

The monospecific antibody of any one of claims 1-11 and 73-77, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 67.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 73, 74, 75, 76, 77, 78)

The monospecific antibody of any one of claims 1-11 and 73-78, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 65 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 67.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 72.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 80)

The monospecific antibody of any one of claims 1-11 and 80, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 72.

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 80)

The monospecific antibody of any one of claims 1-11, 80, and 81, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 72.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 80, 81, 82)

The monospecific antibody of any one of claims 1-11 and 80-82, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 72.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 80, 81, 82, 83)

The monospecific antibody of any one of claims 1-11 and 80-83, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 68 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 72.

### Claim 85 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 80, 81, 82, 83, 84)

The monospecific antibody of any one of claims 1-11 and 80-84, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 71; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 74.

### Claim 86 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 80, 81, 82, 83, 84, 85)

The monospecific antibody of any one of claims 1-11 and 80-85, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 68 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 71; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 72 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 74.

### Claim 87 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 79.

### Claim 88 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 87)

The monospecific antibody of any one of claims 1-11 and 87, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 79.

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 87)

The monospecific antibody of any one of claims 1-11, 87, and 88, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 79.

### Claim 90 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 87, 88, 89)

The monospecific antibody of any one of claims 1-11 and 87-89, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 79.

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 87, 88, 89, 90)

The monospecific antibody of any one of claims 1-11 and 87-90, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 75 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 79.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 87, 88, 89, 90, 91)

The monospecific antibody of any one of claims 1-11 and 87-91, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 78; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 81.

### Claim 93 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 87, 88, 89, 90, 91, 92)

The monospecific antibody of any one of claims 1-11 and 87-92, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 75 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 78; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 79 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 81.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 86.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 94)

The monospecific antibody of any one of claims 1-11 and 94, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 86.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 94)

The monospecific antibody of any one of claims 1-11, 94, and 95, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 86.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 94, 95, 96)

The monospecific antibody of any one of claims 1-11 and 94-96, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 86.

### Claim 98 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 94, 95, 96, 97)

The monospecific antibody of any one of claims 1-11 and 94-97, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 82 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 86.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 94, 95, 96, 97, 98)

The monospecific antibody of any one of claims 1-11 and 94-98, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 85; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 88.

### Claim 100 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 94, 95, 96, 97, 98, 99)

The monospecific antibody of any one of claims 1-11 and 94-99, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 82 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 85; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 86 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 88.

### Claim 101 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 93.

### Claim 102 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 101)

The monospecific antibody of any one of claims 1-11 and 101, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 93.

### Claim 103 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 101)

The monospecific antibody of any one of claims 1-11, 101, and 102, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 93.

### Claim 104 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 101, 102, 103)

The monospecific antibody of any one of claims 1-11 and 101-103, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 93.

### Claim 105 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 101, 102, 103, 104)

The monospecific antibody of any one of claims 1-11 and 101-104, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 89 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 93.

### Claim 106 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 101, 102, 103, 104, 105)

The monospecific antibody of any one of claims 1-11 and 101-105, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 94, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 95.

### Claim 107 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 101, 102, 103, 104, 105, 106)

The monospecific antibody of any one of claims 1-11 and 101-106, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 89 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 93 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 94, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 95.

### Claim 108 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 101, 102, 103, 104, 105, 106, 107)

The monospecific antibody of any one of claims 1-11 and 101-107, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 458, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 478, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 468.

### Claim 109 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 100.

### Claim 110 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 109)

The monospecific antibody of any one of claims 1-11 and 109, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 100.

### Claim 111 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 109)

The monospecific antibody of any one of claims 1-11, 109, and 110, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 100.

### Claim 112 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 109, 110, 111)

The monospecific antibody of any one of claims 1-11 and 109-111, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 100.

### Claim 113 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 109, 110, 111, 112)

The monospecific antibody of any one of claims 1-11 and 109-112, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 96 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 100.

### Claim 114 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 109, 110, 111, 112, 113)

The monospecific antibody of any one of claims 1-11 and 109-113, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 99; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 102.

### Claim 115 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 109, 110, 111, 112, 113, 114)

The monospecific antibody of any one of claims 1-11 and 109-114, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 96 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 99; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 100 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 102.

### Claim 116 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 107.

### Claim 117 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 116)

The monospecific antibody of any one of claims 1-11 and 116, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 107.

### Claim 118 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 116)

The monospecific antibody of any one of claims 1-11, 116, and 117, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 107.

### Claim 119 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 116, 117, 118)

The monospecific antibody of any one of claims 1-11 and 116-118, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 107.

### Claim 120 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 116, 117, 118, 119)

The monospecific antibody of any one of claims 1-11 and 116-119, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 103 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 107.

### Claim 121 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 116, 117, 118, 119, 120)

The monospecific antibody of any one of claims 1-11 and 116-120, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 106; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 109.

### Claim 122 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 116, 117, 118, 119, 120, 121)

The monospecific antibody of any one of claims 1-11 and 116-121, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 103 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 106; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 107 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 109.

### Claim 123 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 114.

### Claim 124 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 123)

The monospecific antibody of any one of claims 1-11 and 123, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 114.

### Claim 125 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 123)

The monospecific antibody of any one of claims 1-11, 123, and 124, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 114.

### Claim 126 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 123, 124, 125)

The monospecific antibody of any one of claims 1-11 and 123-125, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 114.

### Claim 127 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 123, 124, 125, 126)

The monospecific antibody of any one of claims 1-11 and 123-126, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 110 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 114.

### Claim 128 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 123, 124, 125, 126, 127)

The monospecific antibody of any one of claims 1-11 and 123-127, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 116.

### Claim 129 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 123, 124, 125, 126, 127, 128)

The monospecific antibody of any one of claims 1-11 and 123-128, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 110 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 114 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 116.

### Claim 130 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 123, 124, 125, 126, 127, 128, 129)

The monospecific antibody of any one of claims 1-11 and 123-129, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 459, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 479, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 469.

### Claim 131 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 121.

### Claim 132 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 131)

The monospecific antibody of any one of claims 1-11 and 131, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 121.

### Claim 133 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 131)

The monospecific antibody of any one of claims 1-11, 131, and 132, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 121.

### Claim 134 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 131, 132, 133)

The monospecific antibody of any one of claims 1-11 and 131-133, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 121.

### Claim 135 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 131, 132, 133, 134)

The monospecific antibody of any one of claims 1-11 and 131-134, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 117 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 121.

### Claim 136 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 131, 132, 133, 134, 135)

The monospecific antibody of any one of claims 1-11 and 131-135, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 120; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 123.

### Claim 137 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 131, 132, 133, 134, 135, 136)

The monospecific antibody of any one of claims 1-11 and 131-136, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 117 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 120; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 121 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 123.

### Claim 138 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 128.

### Claim 139 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 138)

The monospecific antibody of any one of claims 1-11 and 138, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 128.

### Claim 140 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 138)

The monospecific antibody of any one of claims 1-11, 138, and 139, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 128.

### Claim 141 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 138, 139, 140)

The monospecific antibody of any one of claims 1-11 and 138-140, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 128.

### Claim 142 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 138, 139, 140, 141)

The monospecific antibody of any one of claims 1-11 and 138-141, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 124 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 128.

### Claim 143 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 138, 139, 140, 141, 142)

The monospecific antibody of any one of claims 1-11 and 138-142, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 127; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 130.

### Claim 144 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 138, 139, 140, 141, 142, 143)

The monospecific antibody of any one of claims 1-11 and 138-143, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 124 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 127; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 128 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 131.

### Claim 145 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 135.

### Claim 146 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 145)

The monospecific antibody of any one of claims 1-11 and 145, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 135.

### Claim 147 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 145)

The monospecific antibody of any one of claims 1-11, 145, and 146, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 135.

### Claim 148 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 145, 146, 147)

The monospecific antibody of any one of claims 1-11 and 145-147, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 135.

### Claim 149 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 145, 146, 147, 148)

The monospecific antibody of any one of claims 1-11 and 145-148, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 131 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 135.

### Claim 150 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 145, 146, 147, 148, 149)

The monospecific antibody of any one of claims 1-11 and 145-149, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 134; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 137.

### Claim 151 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 145, 146, 147, 148, 149, 150)

The monospecific antibody of any one of claims 1-11 and 145-150, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 131 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 134; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 135 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 137.

### Claim 152 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 142.

### Claim 153 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 152)

The monospecific antibody of any one of claims 1-11 and 152, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 142.

### Claim 154 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 152)

The monospecific antibody of any one of claims 1-11, 152, and 153, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 142.

### Claim 155 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 152, 153)

The monospecific antibody of any one of claims 1-11 and 152-153, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 142.

### Claim 156 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 152, 153, 154)

The monospecific antibody of any one of claims 1-11 and 152-154, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 138 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 142.

### Claim 157 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 152, 153, 154, 155, 156)

The monospecific antibody of any one of claims 1-11 and 152-156, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 141; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 144.

### Claim 158 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 152, 153, 154, 155, 156, 157)

The monospecific antibody of any one of claims 1-11 and 152-157, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 138 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 141; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 142 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 144.

### Claim 159 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 149.

### Claim 160 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 159)

The monospecific antibody of any one of claims 1-11 and 159, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 149.

### Claim 161 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 159)

The monospecific antibody of any one of claims 1-11, 159, and 160, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 149.

### Claim 162 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 159, 160, 161)

The monospecific antibody of any one of claims 1-11 and 159-161, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 149.

### Claim 163 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 159, 160, 161, 162)

The monospecific antibody of any one of claims 1-11 and 159-162, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 145 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 149.

### Claim 164 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 159, 160, 161, 162, 163)

The monospecific antibody of any one of claims 1-11 and 159-163, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 148; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 151.

### Claim 165 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 159, 160, 161, 162, 163, 164)

The monospecific antibody of any one of claims 1-11 and 159-164, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 145 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 148; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 149 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 151.

### Claim 166 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 156.

### Claim 167 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 166)

The monospecific antibody of any one of claims 1-11 and 166, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 156.

### Claim 168 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 166)

The monospecific antibody of any one of claims 1-11, 166, and 167, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 156.

### Claim 169 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 166, 167, 168)

The monospecific antibody of any one of claims 1-11 and 166-168, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 156.

### Claim 170 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 166, 167, 168, 169)

The monospecific antibody of any one of claims 1-11 and 166-169, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 152 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 156.

### Claim 171 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 166, 167, 168, 169, 170)

The monospecific antibody of any one of claims 1-11 and 166-170, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 155; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 158.

### Claim 172 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 166, 167, 168, 169, 170, 171)

The monospecific antibody of any one of claims 1-11 and 166-171, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 152 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 155; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 156 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 158.

### Claim 173 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 163.

### Claim 174 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 173)

The monospecific antibody of any one of claims 1-11 and 173, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 163.

### Claim 175 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 173)

The monospecific antibody of any one of claims 1-11, 173, and 173, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 163.

### Claim 176 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 173, 174, 175)

The monospecific antibody of any one of claims 1-11 and 173-175, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 163.

### Claim 177 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 173, 174, 175, 176)

The monospecific antibody of any one of claims 1-11 and 173-176, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 159 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 163.

### Claim 178 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 173, 174, 175, 176, 177)

The monospecific antibody of any one of claims 1-11 and 173-177, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 162; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 165.

### Claim 179 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 173, 174, 175, 176, 177, 178)

The monospecific antibody of any one of claims 1-11 and 173-178, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 159 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 162; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 163 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 165.

### Claim 180 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 170.

### Claim 181 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 180)

The monospecific antibody of any one of claims 1-11 and 180, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 170.

### Claim 182 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 180)

The monospecific antibody of any one of claims 1-11, 180, and 181, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 170.

### Claim 183 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 180, 181, 182)

The monospecific antibody of any one of claims 1-11 and 180-182, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 170.

### Claim 184 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 180, 181, 182, 183)

The monospecific antibody of any one of claims 1-11 and 180-183, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 166 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 170.

### Claim 185 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 180, 181, 182, 183, 184)

The monospecific antibody of any one of claims 1-11 and 180-184, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 169; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 172.

### Claim 186 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 180, 181, 182, 183, 184, 185)

The monospecific antibody of any one of claims 1-11 and 180-185, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 166 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 169; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 170 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 172.

### Claim 187 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 177.

### Claim 188 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, and 187, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 177.

### Claim 189 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 187, 188)

The monospecific antibody of any one of claims 1-11, 187 and 187-188, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 177.

### Claim 190 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 187, 188, 189)

The monospecific antibody of any one of claims 1-11 and 187-189, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 177.

### Claim 191 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 187, 188, 189, 190)

The monospecific antibody of any one of claims 1-11 and 187-190, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 173 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 177.

### Claim 192 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 187, 188, 189, 190, 191)

The monospecific antibody of any one of claims 1-11 and 187-191, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 176; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 179.

### Claim 193 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 187, 188, 189, 190, 191, 192)

The monospecific antibody of any one of claims 1-11 and 187-192, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 173 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 176; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 177 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 179.

### Claim 194 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 184.

### Claim 195 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 194)

The monospecific antibody of any one of claims 1-11 and 194, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 184.

### Claim 196 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 194)

The monospecific antibody of any one of claims 1-11, 194, and 195, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 184.

### Claim 197 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 194, 195, 196)

The monospecific antibody of any one of claims 1-11 and 194-196, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 184.

### Claim 198 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 194, 195, 196, 197)

The monospecific antibody of any one of claims 1-11 and 194-197, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 180 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 184.

### Claim 199 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 194, 195, 196, 197, 198)

The monospecific antibody of any one of claims 1-11 and 194-198, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 183; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 186.

### Claim 200 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 194, 195, 196, 197, 198, 199)

The monospecific antibody of any one of claims 1-11 and 194-199, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 180 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 183; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 184 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 186.

### Claim 201 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 191.

### Claim 202 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 201)

The monospecific antibody of any one of claims 1-11 and 201, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 191.

### Claim 203 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 201)

The monospecific antibody of any one of claims 1-11, 201, and 202, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 191.

### Claim 204 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 201, 202, 203)

The monospecific antibody of any one of claims 1-11 and 201-203, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 191.

### Claim 205 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 201, 202, 203, 204)

The monospecific antibody of any one of claims 1-11 and 201-204, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 187 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 191.

### Claim 206 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 201, 202, 203, 204, 205)

The monospecific antibody of any one of claims 1-11 and 201-205, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 190; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 193.

### Claim 207 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 201, 202, 203, 204, 205, 206)

The monospecific antibody of any one of claims 1-11 and 201-206, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 187 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 190; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 191 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 193.

### Claim 208 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 198.

### Claim 209 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 208)

The monospecific antibody of any one of claims 1-11 and 208, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 198.

### Claim 210 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 208)

The monospecific antibody of any one of claims 1-11, 208, and 209, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 198.

### Claim 211 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, and 208-210, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 198.

### Claim 212 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 208, 209, 210, 211)

The monospecific antibody of any one of claims 1-11 and 208-211, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 194 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 198.

### Claim 213 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 208, 209, 210, 211, 212)

The monospecific antibody of any one of claims 1-11 and 208-212, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 197; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 200.

### Claim 214 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 208, 209, 210, 211, 212, 213)

The monospecific antibody of any one of claims 1-11 and 208-213, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 194 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 197; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 198 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 200.

### Claim 215 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 205.

### Claim 216 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 215)

The monospecific antibody of any one of claims 1-11 and 215, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 205.

### Claim 217 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 215)

The monospecific antibody of any one of claims 1-11, 215, and 216, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 205.

### Claim 218 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 215, 216, 217)

The monospecific antibody of any one of claims 1-11 and 215-217, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 205.

### Claim 219 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 215, 216, 217, 218)

The monospecific antibody of any one of claims 1-11 and 215-218, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 201 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 205.

### Claim 220 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 215, 216, 217, 218, 219)

The monospecific antibody of any one of claims 1-11 and 215-219, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 204; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 207.

### Claim 221 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 215, 216, 217, 218, 219, 220)

The monospecific antibody of any one of claims 1-11 and 215-220, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 201 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 204; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 205 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 207.

### Claim 222 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 212.

### Claim 223 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 222)

The monospecific antibody of any one of claims 1-11 and 222, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 212.

### Claim 224 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 222)

The monospecific antibody of any one of claims 1-11, 222, and 223, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 212.

### Claim 225 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 222, 223, 224)

The monospecific antibody of any one of claims 1-11 and 222-224, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 212.

### Claim 226 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 222, 223, 224, 225)

The monospecific antibody of any one of claims 1-11 and 222-225, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 208 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 212.

### Claim 227 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 222, 223, 224, 225, 226)

The monospecific antibody of any one of claims 1-11 and 222-226, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 211; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 212, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 213.

### Claim 228 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 222, 223, 224, 225, 226, 227)

The monospecific antibody of any one of claims 1-11 and 222-227, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 208 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 211; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 212 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 212, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 213.

### Claim 229 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 219.

### Claim 230 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 229)

The monospecific antibody of any one of claims 1-11 and 229, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 219.

### Claim 231 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 229)

The monospecific antibody of any one of claims 1-11, 229, and 203, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 219.

### Claim 232 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 229, 230, 231)

The monospecific antibody of any one of claims 1-11 and 229-231, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 219.

### Claim 233 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 229, 230, 231, 232)

The monospecific antibody of any one of claims 1-11 and 229-232, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 215 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 219.

### Claim 234 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 229, 230, 231, 232, 233)

The monospecific antibody of any one of claims 1-11 and 229-233, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 218; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 221.

### Claim 235 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 229, 230, 231, 232, 233, 234)

The monospecific antibody of any one of claims 1-11 and 229-234, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 215 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 218; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 219 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 221.

### Claim 236 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 226.

### Claim 237 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 236)

The monospecific antibody of any one of claims 1-11 and 236, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 226.

### Claim 238 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 236)

The monospecific antibody of any one of claims 1-11, 236, and 237, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 226.

### Claim 239 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 236, 237, 238)

The monospecific antibody of any one of claims 1-11 and 236-238, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 226.

### Claim 240 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 236, 237, 238, 239)

The monospecific antibody of any one of claims 1-11 and 236-239, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 222 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 226.

### Claim 241 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 236, 237, 238, 239, 240)

The monospecific antibody of any one of claims 1-11 and 236-240, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 225; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 228.

### Claim 242 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 236, 237, 238, 239, 240, 241)

The monospecific antibody of any one of claims 1-11 and 236-241, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 222 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 225; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 226 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 228.

### Claim 243 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 233.

### Claim 244 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 243)

The monospecific antibody of any one of claims 1-11 and 243, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 233.

### Claim 245 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 243)

The monospecific antibody of any one of claims 1-11, 243, and 244, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 233.

### Claim 246 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 243, 244, 245)

The monospecific antibody of any one of claims 1-11 and 243-245, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 233.

### Claim 247 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 243, 244, 245, 246)

The monospecific antibody of any one of claims 1-11 and 243-246, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 229 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 233.

### Claim 248 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 243, 244, 245, 246, 247)

The monospecific antibody of any one of claims 1-11 and 243-247, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 232; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 235.

### Claim 249 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 243, 244, 245, 246, 247, 248)

The monospecific antibody of any one of claims 1-11 and 243-248, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 229 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 232; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 233 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 235.

### Claim 250 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 240.

### Claim 251 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 250)

The monospecific antibody of any one of claims 1-11 and 250, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 240.

### Claim 252 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 250)

The monospecific antibody of any one of claims 1-11, 250, and 251, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 240.

### Claim 253 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 250, 251, 252)

The monospecific antibody of any one of claims 1-11 and 250-252, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 240.

### Claim 254 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 250, 251, 252, 253)

The monospecific antibody of any one of claims 1-11 and 250-253, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 236 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 240.

### Claim 255 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 250, 251, 252, 253, 254)

The monospecific antibody of any one of claims 1-11 and 250-254, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 239; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 242.

### Claim 256 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 250, 251, 252, 253, 254, 255)

The monospecific antibody of any one of claims 1-11 and 250-255, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 236 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 239; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 240 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 242.

### Claim 257 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 247.

### Claim 258 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 257)

The monospecific antibody of any one of claims 1-11 and 257, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 247.

### Claim 259 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 257)

The monospecific antibody of any one of claims 1-11, 257, and 258, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 247.

### Claim 260 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 257, 258, 259)

The monospecific antibody of any one of claims 1-11 and 257-259, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 247.

### Claim 261 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 257, 258, 259, 260)

The monospecific antibody of any one of claims 1-11 and 257-260, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 243 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 247.

### Claim 262 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 257, 258, 259, 260, 261)

The monospecific antibody of any one of claims 1-11 and 257-261, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 246; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 249.

### Claim 263 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 257, 258, 259, 260, 261, 262)

The monospecific antibody of any one of claims 1-11 and 257-262, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 243 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 246; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 247 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 249.

### Claim 264 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 257, 258, 259, 260, 261, 262, 263)

The monospecific antibody of any one of claims 1-11 and 257-263, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 460, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 480, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 470.

### Claim 265 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 254.

### Claim 266 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 265)

The monospecific antibody of any one of claims 1-11 and 265, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 254.

### Claim 267 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 265)

The monospecific antibody of any one of claims 1-11, 265, and 266, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 254.

### Claim 268 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 265, 266, 267)

The monospecific antibody of any one of claims 1-11 and 265-267, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 254.

### Claim 269 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 265, 266, 267, 268)

The monospecific antibody of any one of claims 1-11 and 265-268, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 250 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 254.

### Claim 270 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 265, 266, 267, 268, 269)

The monospecific antibody of any one of claims 1-11 and 265-269, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 253; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 256.

### Claim 271 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 265, 266, 267, 268, 269, 270)

The monospecific antibody of any one of claims 1-11 and 265-270, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 250 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 253; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 254 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 256.

### Claim 272 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 261.

### Claim 273 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 272)

The monospecific antibody of any one of claims 1-11 and 272, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 261.

### Claim 274 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 272)

The monospecific antibody of any one of claims 1-11, 272, and 273, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 261.

### Claim 275 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 272, 273, 274)

The monospecific antibody of any one of claims 1-11 and 272-274, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 261.

### Claim 276 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 272, 273, 274, 275)

The monospecific antibody of any one of claims 1-11 and 272-275, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 257 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 261.

### Claim 277 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 272, 273, 274, 275, 276)

The monospecific antibody of any one of claims 1-11 and 272-276, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 260; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 263.

### Claim 278 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 272, 273, 274, 275, 276, 277)

The monospecific antibody of any one of claims 1-11 and 272-277, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 257 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 260; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 261 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 263.

### Claim 279 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 268.

### Claim 280 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 279)

The monospecific antibody of any one of claims 1-11 and 279, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 268.

### Claim 281 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 279)

The monospecific antibody of any one of claims 1-11, 279, and 280, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 268.

### Claim 282 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 279, 280, 281)

The monospecific antibody of any one of claims 1-11 and 279-281, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 268.

### Claim 283 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 279, 280, 281, 282)

The monospecific antibody of any one of claims 1-11 and 279-282, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 264 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 268.

### Claim 284 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 279, 280, 281, 282, 283)

The monospecific antibody of any one of claims 1-11 and 279-283, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 267; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 270.

### Claim 285 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 279, 280, 281, 282, 283, 284)

The monospecific antibody of any one of claims 1-11 and 279-284, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 264 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 267; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 268 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 270.

### Claim 286 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 275.

### Claim 287 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 286)

The monospecific antibody of any one of claims 1-11 and 286, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 275.

### Claim 288 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 286)

The monospecific antibody of any one of claims 1-11, 286, and 287, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 275.

### Claim 289 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 286, 287, 288)

The monospecific antibody of any one of claims 1-11 and 286-288, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 275.

### Claim 290 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 286, 287, 288, 289)

The monospecific antibody of any one of claims 1-11 and 286-289, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 271 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 275.

### Claim 291 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 286, 287, 288, 289, 290)

The monospecific antibody of any one of claims 1-11 and 286-290, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 274; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 277.

### Claim 292 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 286, 287, 288, 289, 290, 291)

The monospecific antibody of any one of claims 1-11 and 286-291, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 271 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 274; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 275 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 277.

### Claim 293 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 282.

### Claim 294 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 293)

The monospecific antibody of any one of claims 1-11 and 293, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 282.

### Claim 295 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 293)

The monospecific antibody of any one of claims 1-11, 293, and 294, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 282.

### Claim 296 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 293, 294, 295)

The monospecific antibody of any one of claims 1-11 and 293-295, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 282.

### Claim 297 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 293, 294, 295, 296)

The monospecific antibody of any one of claims 1-11 and 293-296, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 278 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 282.

### Claim 298 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 293, 294, 295, 296, 297)

The monospecific antibody of any one of claims 1-11 and 293-297, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 281; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 284.

### Claim 299 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 293, 294, 295, 296, 297, 298)

The monospecific antibody of any one of claims 1-11 and 293-298, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 278 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 281; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 282 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 284.

### Claim 300 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 289.

### Claim 301 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 300)

The monospecific antibody of any one of claims 1-11 and 300, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 289.

### Claim 302 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 300)

The monospecific antibody of any one of claims 1-11, 300, and 301, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 289.

### Claim 303 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 300, 301, 302)

The monospecific antibody of any one of claims 1-11 and 300-302, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 289.

### Claim 304 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 300, 301, 302, 303)

The monospecific antibody of any one of claims 1-11 and 300-303, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 285 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 289.

### Claim 305 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 300, 301, 302, 303, 304)

The monospecific antibody of any one of claims 1-11 and 300-304, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 288; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 291.

### Claim 306 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 300, 301, 302, 303, 304, 305)

The monospecific antibody of any one of claims 1-11 and 300-305, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 285 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 288; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 289 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 291.

### Claim 307 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 296.

### Claim 308 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 307)

The monospecific antibody of any one of claims 1-11 and 307, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 296.

### Claim 309 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 307)

The monospecific antibody of any one of claims 1-11, 307, and 308, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 296.

### Claim 310 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 307, 308, 309)

The monospecific antibody of any one of claims 1-11 and 307-309, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 296.

### Claim 311 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 307, 308, 309, 310)

The monospecific antibody of any one of claims 1-11 and 307-310, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 292 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 296.

### Claim 312 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 307, 308, 309, 310, 311)

The monospecific antibody of any one of claims 1-11 and 307-311, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 295; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 297, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 298.

### Claim 313 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 307, 308, 309, 310, 311, 312)

The monospecific antibody of any one of claims 1-11 and 307-312, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 292 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 295; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 296 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 297, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 298.

### Claim 314 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 303.

### Claim 315 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 314)

The monospecific antibody of any one of claims 1-11 and 314, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 303.

### Claim 316 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 314)

The monospecific antibody of any one of claims 1-11, 314, and 315, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 303.

### Claim 317 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 314, 315, 316)

The monospecific antibody of any one of claims 1-11 and 314-316, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 303.

### Claim 318 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 314, 315, 316, 317)

The monospecific antibody of any one of claims 1-11 and 314-317, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 299 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 303.

### Claim 319 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 314, 315, 316, 317, 318)

The monospecific antibody of any one of claims 1-11 and 314-318, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 302; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 305.

### Claim 320 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 314, 315, 316, 317, 318, 319)

The monospecific antibody of any one of claims 1-11 and 314-319, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 299 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 302; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 303 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 305.

### Claim 321 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 310.

### Claim 322 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, and 321, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 310.

### Claim 323 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 321)

The monospecific antibody of any one of claims 1-11, 321, and 322, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 310.

### Claim 324 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 321, 322, 323)

The monospecific antibody of any one of claims 1-11 and 321-323, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 310.

### Claim 325 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 321, 322, 323, 324)

The monospecific antibody of any one of claims 1-11 and 321-324, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 306 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 310.

### Claim 326 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 321, 322, 323, 324, 325)

The monospecific antibody of any one of claims 1-11 and 321-325, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 309; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 312.

### Claim 327 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 321, 322, 323, 324, 325, 326)

The monospecific antibody of any one of claims 1-11 and 321-326, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 306 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 309; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 310 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 312.

### Claim 328 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 321, 322, 323, 324, 325, 326, 327)

The monospecific antibody of any one of claims 1-11 and 321-327, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 461, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 481, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 471.

### Claim 329 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 317.

### Claim 330 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 329)

The monospecific antibody of any one of claims 1-11 and 329, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 317.

### Claim 331 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 329)

The monospecific antibody of any one of claims 1-11, 329, and 330, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 317.

### Claim 332 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 329, 330, 331)

The monospecific antibody of any one of claims 1-11 and 329-331, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 317.

### Claim 333 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 329, 330, 331, 332)

The monospecific antibody of any one of claims 1-11 and 329-332, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 313 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 317.

### Claim 334 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 329, 330, 331, 332, 333)

The monospecific antibody of any one of claims 1-11 and 329-333, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 316; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 319.

### Claim 335 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 329, 330, 331, 332, 333, 334)

The monospecific antibody of any one of claims 1-11 and 329-334, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 313 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 316; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 317 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 319.

### Claim 336 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 324.

### Claim 337 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 336)

The monospecific antibody of any one of claims 1-11 and 336, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 324.

### Claim 338 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 336)

The monospecific antibody of any one of claims 1-11, 336, and 337, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 324.

### Claim 339 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 336, 337, 338)

The monospecific antibody of any one of claims 1-11 and 336-338, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 324.

### Claim 340 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 336, 337, 338, 339)

The monospecific antibody of any one of claims 1-11 and 336-339, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 320 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 324.

### Claim 341 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 336, 337, 338, 339, 340)

The monospecific antibody of any one of claims 1-11 and 336-340, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 323; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 326.

### Claim 342 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 336, 337, 338, 339, 340, 341)

The monospecific antibody of any one of claims 1-11 and 336-341, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 320 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 323; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 324 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 326.

### Claim 343 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 331.

### Claim 344 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 343)

The monospecific antibody of any one of claims 1-11 and 343, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 331.

### Claim 345 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 343)

The monospecific antibody of any one of claims 1-11, 343, and 344, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 331.

### Claim 346 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 343, 344, 345)

The monospecific antibody of any one of claims 1-11 and 343-345, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 331.

### Claim 347 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 343, 344, 345, 346)

The monospecific antibody of any one of claims 1-11 and 343-346, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 327 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 331.

### Claim 348 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 343, 344, 345, 346, 347)

The monospecific antibody of any one of claims 1-11 and 343-347, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 330; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 333.

### Claim 349 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 343, 344, 345, 346, 347, 348)

The monospecific antibody of any one of claims 1-11 and 343-348, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 327 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 330; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 331 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 333.

### Claim 350 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 338.

### Claim 351 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 350)

The monospecific antibody of any one of claims 1-11 and 350, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 338.

### Claim 352 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 350)

The monospecific antibody of any one of claims 1-11, 350, and 351, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 338.

### Claim 353 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 350, 351, 352)

The monospecific antibody of any one of claims 1-11 and 350-352, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 338.

### Claim 354 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 350, 351, 352, 353)

The monospecific antibody of any one of claims 1-11 and 350-353, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 334 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 338.

### Claim 355 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 350, 351, 352, 353, 354)

The monospecific antibody of any one of claims 1-11 and 350-354, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 337; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 340.

### Claim 356 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 350, 351, 352, 353, 354, 355)

The monospecific antibody of any one of claims 1-11 and 350-355, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 334 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 337; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 338 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 340.

### Claim 357 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 345.

### Claim 358 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 357)

The monospecific antibody of any one of claims 1-11 and 357, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 345.

### Claim 359 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 357)

The monospecific antibody of any one of claims 1-11, 357, and 358, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 345.

### Claim 360 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 357, 358, 359)

The monospecific antibody of any one of claims 1-11 and 357-359, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 345.

### Claim 361 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 357, 358, 359, 360)

The monospecific antibody of any one of claims 1-11 and 357-360, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 341 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 345.

### Claim 362 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 357, 358, 359, 360, 361)

The monospecific antibody of any one of claims 1-11 and 357-361, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 344; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 347.

### Claim 363 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 357, 358, 359, 360, 361, 362)

The monospecific antibody of any one of claims 1-11 and 357-362, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 341 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 344; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 345 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 347.

### Claim 364 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 352.

### Claim 365 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 364)

The monospecific antibody of any one of claims 1-11 and 364, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 352.

### Claim 366 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 364)

The monospecific antibody of any one of claims 1-11, 364, and 365, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 352.

### Claim 367 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 364, 365, 366)

The monospecific antibody of any one of claims 1-11 and 364-366, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 352.

### Claim 368 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 364, 365, 366, 367)

The monospecific antibody of any one of claims 1-11 and 364-367, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 348 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 352.

### Claim 369 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 364, 365, 366, 367, 368)

The monospecific antibody of any one of claims 1-11 and 364-368, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 351; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 354.

### Claim 370 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 364, 365, 366, 367, 368, 369)

The monospecific antibody of any one of claims 1-11 and 364-369, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 348 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 351; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 352 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 354.

### Claim 371 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 359.

### Claim 372 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 371)

The monospecific antibody of any one of claims 1-11 and 371, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 359.

### Claim 373 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 371)

The monospecific antibody of any one of claims 1-11, 371, and 372, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 359.

### Claim 374 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 371, 372, 373)

The monospecific antibody of any one of claims 1-11 and 371-373, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 359.

### Claim 375 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 371, 372, 373, 374)

The monospecific antibody of any one of claims 1-11 and 371-374, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 355 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 359.

### Claim 376 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 371, 372, 373, 374, 375)

The monospecific antibody of any one of claims 1-11 and 371-375, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 358; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 361.

### Claim 377 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 371, 372, 373, 374, 375, 376, 377, 378)

The monospecific antibody of any one of claims 1-11 and 371-378, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 355 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 358; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 359 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 361.

### Claim 378 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 366.

### Claim 379 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 378)

The monospecific antibody of any one of claims 1-11 and 378, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 366.

### Claim 380 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 378)

The monospecific antibody of any one of claims 1-11, 378, and 379, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 366.

### Claim 381 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 378, 379, 380)

The monospecific antibody of any one of claims 1-11 and 378-380, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 366.

### Claim 382 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 378, 379, 380, 381)

The monospecific antibody of any one of claims 1-11 and 378-381, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 362 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 366.

### Claim 383 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 378, 379, 380, 381, 382)

The monospecific antibody of any one of claims 1-11 and 378-382, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 365; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 368.

### Claim 384 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 378, 379, 380, 381, 382, 383)

The monospecific antibody of any one of claims 1-11 and 378-383, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 362 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 365; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 366 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 368.

### Claim 385 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 373.

### Claim 386 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 385)

The monospecific antibody of any one of claims 1-11 and 385, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 373.

### Claim 387 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 385)

The monospecific antibody of any one of claims 1-11, 385, and 386, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 373.

### Claim 388 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 385, 386, 387)

The monospecific antibody of any one of claims 1-11 and 385-387, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 373.

### Claim 389 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 385, 386, 387, 388)

The monospecific antibody of any one of claims 1-11 and 385-388, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 369 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 373.

### Claim 390 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 385, 386, 387, 388, 389)

The monospecific antibody of any one of claims 1-11 and 385-389, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 372; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 375.

### Claim 391 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 380, 385)

The monospecific antibody of any one of claims 1-11 and 385-380, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 369 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 372; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 373 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 375.

### Claim 392 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 380.

### Claim 393 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 392)

The monospecific antibody of any one of claims 1-11 and 392, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 380.

### Claim 394 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 392)

The monospecific antibody of any one of claims 1-11, 392, and 393, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 380.

### Claim 395 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 392, 393, 394)

The monospecific antibody of any one of claims 1-11 and 392-394, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 380.

### Claim 396 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 392, 393, 394, 395)

The monospecific antibody of any one of claims 1-11 and 392-395, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 376 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 380.

### Claim 397 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 392, 393, 394, 395, 396)

The monospecific antibody of any one of claims 1-11 and 392-396, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 379; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 382.

### Claim 398 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 392, 393, 394, 395, 396, 397)

The monospecific antibody of any one of claims 1-11 and 392-397, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 376 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 379; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 380 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 382.

### Claim 399 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 387.

### Claim 400 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 399)

The monospecific antibody of any one of claims 1-11 and 399, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 387.

### Claim 401 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 399)

The monospecific antibody of any one of claims 1-11, 399, and 400, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 387.

### Claim 402 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 399, 400, 401)

The monospecific antibody of any one of claims 1-11 and 399-401, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 387.

### Claim 403 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 399, 400, 401, 402)

The monospecific antibody of any one of claims 1-11 and 399-402, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 383 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 387.

### Claim 404 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 399, 400, 401, 402, 403)

The monospecific antibody of any one of claims 1-11 and 399-403, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 386; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 389.

### Claim 405 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 399, 400, 401, 402, 403, 404)

The monospecific antibody of any one of claims 1-11 and 399-404, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 383 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 386; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 387 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 389.

### Claim 406 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 394.

### Claim 407 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 406)

The monospecific antibody of any one of claims 1-11 and 406, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 394.

### Claim 408 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 406)

The monospecific antibody of any one of claims 1-11, 406, and 407, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 394.

### Claim 409 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 406, 407, 408)

The monospecific antibody of any one of claims 1-11 and 406-408, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 394.

### Claim 410 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 406, 407, 408, 409)

The monospecific antibody of any one of claims 1-11 and 406-409, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 390 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 394.

### Claim 411 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 406, 407, 408, 409, 410)

The monospecific antibody of any one of claims 1-11 and 406-410, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 393; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 396.

### Claim 412 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 406, 407, 408, 409, 410, 411)

The monospecific antibody of any one of claims 1-11 and 406-411, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 390 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 393; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 394 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 396.

### Claim 413 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 406, 407, 408, 409, 410, 411, 412)

The monospecific antibody of any one of claims 1-11 and 406-412, wherein the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 462, a second heavy chain region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 482, and a light chain (LC) region, comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 472.

### Claim 414 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 401.

### Claim 415 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 414)

The monospecific antibody of any one of claims 1-11 and 414, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 401.

### Claim 416 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 414)

The monospecific antibody of any one of claims 1-11, 414, and 415, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 401.

### Claim 417 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 414, 415, 416)

The monospecific antibody of any one of claims 1-11 and 414-416, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 401.

### Claim 418 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 414, 415, 416, 417)

The monospecific antibody of any one of claims 1-11 and 414-417, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 397 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 401.

### Claim 419 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 414, 415, 416, 417, 418)

The monospecific antibody of any one of claims 1-11 and 414-418, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 400; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 403.

### Claim 420 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 414, 415, 416, 417, 418, 419)

The monospecific antibody of any one of claims 1-11 and 414-419, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 397 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 400; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 401 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 403.

### Claim 421 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 408.

### Claim 422 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 421)

The monospecific antibody of any one of claims 1-11 and 421, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 408.

### Claim 423 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 421)

The monospecific antibody of any one of claims 1-11, 421, and 422, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 408.

### Claim 424 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 421, 422, 423)

The monospecific antibody of any one of claims 1-11 and 421-423, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 408.

### Claim 425 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 421, 422, 423, 424)

The monospecific antibody of any one of claims 1-11 and 421-424, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 404 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 408.

### Claim 426 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 421, 422, 423, 424, 425)

The monospecific antibody of any one of claims 1-11 and 421-425, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 407; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 410.

### Claim 427 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 421, 422, 423, 424, 425, 426)

The monospecific antibody of any one of claims 1-11 and 421-426, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 404 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 407; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 408 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 410.

### Claim 428 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 415.

### Claim 429 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 428)

The monospecific antibody of any one of claims 1-11 and 428, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 415.

### Claim 430 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 428)

The monospecific antibody of any one of claims 1-11, 428, and 428, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 415.

### Claim 431 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 428, 429, 430)

The monospecific antibody of any one of claims 1-11 and 428-430, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 415.

### Claim 432 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 428, 429, 430, 431)

The monospecific antibody of any one of claims 1-11 and 428-431, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 411 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 415.

### Claim 433 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 428, 429, 430, 431, 432)

The monospecific antibody of any one of claims 1-11 and 428-432, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 414; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 416, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 417.

### Claim 434 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 428, 429, 430, 431, 432, 433)

The monospecific antibody of any one of claims 1-11 and 428-433, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 411 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 414; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 415 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 416, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 417.

### Claim 435 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 422.

### Claim 436 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 435)

The monospecific antibody of any one of claims 1-11 and 435, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 422.

### Claim 437 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 435)

The monospecific antibody of any one of claims 1-11, 435, and 436, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 422.

### Claim 438 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 435, 436, 437)

The monospecific antibody of any one of claims 1-11 and 435-437, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 422.

### Claim 439 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 435, 436, 437, 438)

The monospecific antibody of any one of claims 1-11 and 435-438, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 418 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 422.

### Claim 440 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 435, 436, 437, 438, 439)

The monospecific antibody of any one of claims 1-11 and 435-439, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 421; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 424.

### Claim 441 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 435, 436, 437, 438, 439, 440)

The monospecific antibody of any one of claims 1-11 and 435-440, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 418 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 421; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 422 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 424.

### Claim 442 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 429.

### Claim 443 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 442)

The monospecific antibody of any one of claims 1-11 and 442, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 429.

### Claim 444 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 442)

The monospecific antibody of any one of claims 1-11, 442, and 443, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 429.

### Claim 445 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 442, 443, 444)

The monospecific antibody of any one of claims 1-11 and 442-444, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 429.

### Claim 446 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 442, 443, 444, 445)

The monospecific antibody of any one of claims 1-11 and 442-445, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 425 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 429.

### Claim 447 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 442, 443, 444, 445, 446)

The monospecific antibody of any one of claims 1-11 and 442-446, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 428; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 431.

### Claim 448 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 442, 443, 444, 445, 446, 447)

The monospecific antibody of any one of claims 1-11 and 442-447, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 425 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 428; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 429 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 431.

### Claim 449 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 436.

### Claim 450 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 449)

The monospecific antibody of any one of claims 1-11 and 449, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 436.

### Claim 451 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 449)

The monospecific antibody of any one of claims 1-11, 449, and 450, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 436.

### Claim 452 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 449, 450, 451)

The monospecific antibody of any one of claims 1-11 and 449-451, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 436.

### Claim 453 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 449, 450, 451, 452)

The monospecific antibody of any one of claims 1-11 and 449-452, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 432 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 436.

### Claim 454 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 449, 450, 451, 452, 453)

The monospecific antibody of any one of claims 1-11 and 449-453, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 435; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 438.

### Claim 455 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 449, 450, 451, 452, 453, 454)

The monospecific antibody of any one of claims 1-11 and 449-454, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 432 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 435; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 436 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 438.

### Claim 456 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 443.

### Claim 457 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 456)

The monospecific antibody of any one of claims 1-11 and 456, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 443.

### Claim 458 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 456)

The monospecific antibody of any one of claims 1-11, 456, and 457, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 443.

### Claim 459 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 456, 457, 458)

The monospecific antibody of any one of claims 1-11 and 456-458, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 443.

### Claim 460 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 456, 457, 458, 459)

The monospecific antibody of any one of claims 1-11 and 456-459, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 439 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 443.

### Claim 461 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 456, 457, 458, 459, 460)

The monospecific antibody of any one of claims 1-11 and 456-460, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 442; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 445.

### Claim 462 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 456, 457, 458, 459, 460, 461)

The monospecific antibody of any one of claims 1-11 and 456-461, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 439 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 442; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 443 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 445.

### Claim 463 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 450.

### Claim 464 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 463)

The monospecific antibody of any one of claims 1-11 and 463, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 450.

### Claim 465 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 463)

The monospecific antibody of any one of claims 1-11, 463, and 464, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 450.

### Claim 466 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 463, 464, 465)

The monospecific antibody of any one of claims 1-11 and 463-465, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 450.

### Claim 467 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 463, 464, 465, 466)

The monospecific antibody of any one of claims 1-11 and 463-466, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 446 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 450.

### Claim 468 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 463, 464, 465, 466, 467)

The monospecific antibody of any one of claims 1-11 and 463-467, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 449; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 452.

### Claim 469 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 463, 464, 465, 466, 467, 468)

The monospecific antibody of any one of claims 1-11 and 463-468, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 446 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 449; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 450 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 452.

### Claim 470 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 65.

### Claim 471 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The monospecific antibody of any one of claims 1-11, and 470, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 85% identity to SEQ ID NO: 65.

### Claim 472 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 470, 471)

The monospecific antibody of any one of claims 1-11, 470 and 470-471, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 90% identity to SEQ ID NO: 65.

### Claim 473 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 470, 471, 472)

The monospecific antibody of any one of claims 1-11 and 470-472, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence with at least 95% identity to SEQ ID NO: 65.

### Claim 474 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 470, 471, 472, 473)

The monospecific antibody of any one of claims 1-11 and 470-473, wherein the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 61 and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 65.

### Claim 475 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 470, 471, 472, 473, 474)

The monospecific antibody of any one of claims 1-11 and 470-474, wherein the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 67.

### Claim 476 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 470, 471, 472, 473, 474, 475)

The monospecific antibody of any one of claims 1-11 and 470-475, wherein the antibody comprises: (a) a variable heavy chain (VH) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 61 and comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64; a variable light chain (VL) region having an amino acid sequence with at least 80% identity to SEQ ID NO: 65 and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 67.

### Claim 477 (depends on 1, 476)

The monospecific antibody of any one of claims 1-476, wherein the antibody binds to one or more amino acid residues of the VWF CK domain selected from D2726, R2730, K2735, E2744, D2746, K2757, D2763, and T2789.

### Claim 478 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWF CK domain: D2726, R2730, D2746, and K2757.

### Claim 479 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWF CK domain: R2730, K2735, E2744, and D2746.

### Claim 480 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWF CK domain: K2735, D2746, and K2757.

### Claim 481 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWF CK domain: R2730, D2746, and K2757.

### Claim 482 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWF CK domain: K2735, E2744, D2746, and D2763.

### Claim 483 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWF CK domain: R2730, K2735, E2744, D2746, K2757, and D2763.

### Claim 484 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least amino acid residue K2735 of the VWF CK domain.

### Claim 485 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWF CK domain: D2726, K2735, and K2757.

### Claim 486 (depends on 1, 477)

The monospecific antibody of any one of claims 1-477, wherein the antibody binds to at least the following amino acid residues of the VWF CK domain: K2735 and D2763.

### Claim 487 (depends on 1, 486)

The monospecific antibody of any one of claims 1-486, wherein binding of the antibody to the VWF protein does not result in a change in function of the VWF protein.

### Claim 488 (depends on 1, 487)

The monospecific antibody of any one of claims 1-487, wherein binding of the antibody to the VWF protein does not inhibit VWF protein binding to one or more binding partners.

### Claim 489 (depends on 488)

The monospecific antibody of claim 488, wherein the one or more binding partners are selected from the group consisting of Factor VIII, collagen, glycoprotein Ib (gp1b), glycoprotein IIb/IIIa (gpIIb/IIIa), and ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13 (ADAMTS13).

### Claim 490 (depends on 487, 488, 489)

The monospecific antibody of any one of claims 487-489, wherein binding of the antibody to the VWF protein does not inhibit VWF protein binding to platelet cells.

### Claim 491 (depends on 1, 490)

The monospecific antibody of any one of claims 1-490, wherein the accumulation of the VWF protein in blood plasma results in a blood plasma level of the VWF protein that is at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater as compared to a blood plasma level of the VWF protein in the absence of the antibody.

### Claim 492 (depends on 1, 490)

The monospecific antibody of any one of claims 1-490, wherein the accumulation of the VWF protein in blood plasma results in a blood plasma level of the VWF protein that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000%, or greater as compared to a blood plasma level of the VWF protein in the absence of the antibody.

### Claim 493 (depends on 1, 492)

The monospecific antibody of any one of claims 1-492, wherein binding of the antibody to the VWF protein in blood plasma increases a blood plasma half-life of the VWF protein as compared to a blood plasma half-life of the VWF protein in the absence of the antibody.

### Claim 494 (depends on 493)

The monospecific antibody of claim 493, wherein binding of the antibody to the VWF protein in blood plasma increases the blood plasma half-life of the VWF protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold or more as compared to the blood plasma half-life of the VWF protein in the absence of the antibody.

### Claim 495 (depends on 493)

The monospecific antibody of claim 493, wherein binding of the antibody to the VWF protein in blood plasma increases the blood plasma half-life of the VWF protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, or 10,000% or more as compared to the blood plasma half-life of the VWF protein in the absence of the antibody.

### Claim 496 (depends on 1, 495)

The monospecific antibody of any one of claims 1-495, wherein binding of the antibody to the VWF protein in blood plasma results in accumulation of a Factor VIII (FVIII) protein in blood plasma as compared to a blood plasma level of a FVIII protein in the absence of the antibody.

### Claim 497 (depends on 496)

The monospecific antibody of claim 496, wherein the accumulation of the FVIII protein in blood plasma results in a blood plasma level of the Factor VIII protein that is at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater as compared to a blood plasma level of the FVIII protein in the absence of the antibody.

### Claim 498 (depends on 496)

The monospecific antibody of claim 496, wherein the accumulation of the FVIII protein in blood plasma results in a blood plasma level of the FVIII protein that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000%, or greater as compared to the blood plasma level of a FVIII protein in the absence of the antibody.

### Claim 499 (depends on 1, 598)

The monospecific antibody of any one of claims 1-598, wherein binding of the antibody to the VWF protein in blood plasma increases the blood plasma half-life of a FVIII protein as compared to the blood plasma half-life of the FVIII protein in the absence of the antibody.

### Claim 500 (depends on 499)

The monospecific antibody of claim 499, wherein binding of the antibody to the VWF protein in blood plasma increases the blood plasma half-life of the FVIII protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold or more as compared to the blood plasma half-life of the FVIII protein in the absence of the antibody.

### Claim 501 (depends on 499)

The monospecific antibody of claim 499, wherein binding of the antibody to the VWF protein in blood plasma increases the blood plasma half-life of the FVIII protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, or 10,000% or more as compared to the blood plasma half-life of the FVIII protein in the absence of the antibody.

### Claim 502 (depends on 1, 501)

The monospecific antibody of any one of claims 1-501, wherein the antibody binds specifically to a VWF homodimer comprising two VWF monomers linked tail-to-tail via CK-domain joining in a 1:1 stoichiometry.

### Claim 503 (depends on 1, 501)

The monospecific antibody of any one of claims 1-501, wherein the antibody binds specifically to a VWF homodimer comprising two VWF monomers linked tail-to-tail via CK-domain joining in a 2:1 stoichiometry.

### Claim 504 (depends on 1, 503)

The monospecific antibody of any one of claims 1-503, wherein the antibody binds to the CK domain of the VWF protein with a dissociation constant (Kd) of less than 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 7 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.25 nM, 0.1 nM, 0.075 nM, 0.05 nM, 0.025 nM, 0.01 nM, or less.

### Claim 505 (depends on 1, 504)

The monospecific antibody of any one of claims 1-504, wherein the antibody is cross-reactive with a VWF protein of Macaca fascicularis, Mus musculus, and/or Canis familiaris.

### Claim 506 (depends on 505)

The monospecific antibody of claim 505, wherein the antibody exhibits an affinity to the VWF protein of Macaca fascicularis, Mus musculus, and/or Canis familiaris that is at most 10-fold lower than an affinity of the antibody to a human VWF protein.

### Claim 507 (depends on 1, 506)

The monospecific antibody of any one of claims 1-506, wherein the antibody is a human antibody, humanized antibody, or chimeric antibody.

### Claim 508 (depends on 1, 507)

The monospecific antibody of any one of claims 1-507, wherein the CK domain has an amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.

### Claim 509 (depends on 1, 508)

A complex comprising a VWF protein and a monospecific antibody of any one of claims 1-508.

### Claim 510 (depends on 1, 508)

A pharmaceutical composition comprising the monospecific antibody of any one of claims 1-508 and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 511 (depends on 510)

The pharmaceutical composition of claim 510, wherein the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of a stabilizer, buffer, surfactant, filler, solvent, tonicity or osmolarity adjusting agent, antioxidant, adjuvant, and antimicrobial agent.

### Claim 512 (depends on 1, 508, 510, 511)

A method of treating a blood disorder characterized by excessive bleeding in a subject in need thereof, comprising administering to the subject the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511.

### Claim 513 (depends on 512)

The method of claim 512, wherein the blood disorder is selected from the group consisting of von Willebrand disease (VWD), Heydes syndrome, hemophilia A, disorders of platelet function, and connective tissue disorders.

### Claim 514 (depends on 513)

The method of claim 513, wherein the VWD is congenital VWD (cVWD) or acquired VWD (aVWD).

### Claim 515 (depends on 513, 514)

The method of claim 513 or 514, wherein the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

### Claim 516 (depends on 512, 513, 514, 515)

The method of any one of claims 512-515, wherein the composition treats one or more symptoms of the blood disorder selected from the group consisting of epistaxis, cutaneous bleeding, bleeding from minor wounds, oral-cavity bleeding, angiodysplasia, gastrointestinal bleeding, bleeding from tooth extraction, postoperative bleeding, heavy menstrual bleeding, obstetric hemorrhage, hematuria, muscle hematoma, joint bleeding, visceral bleeding, and central nervous system (CNS) bleeding.

### Claim 517 (depends on 512, 513, 514, 515, 516)

The method of any one of claims 512-516, wherein the composition or pharmaceutical composition promotes platelet adhesion and/or aggregation in the subject.

### Claim 518 (depends on 1, 508, 510, 511)

A method of accumulating a VWF protein in blood plasma of a subject in need thereof, comprising administering to the subject a composition comprising the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511.

### Claim 519 (depends on 1, 508, 510, 511)

A method of accumulating a FVIII protein in blood plasma of a subject in need thereof, comprising administering to the subject a composition comprising the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511.

### Claim 520 (depends on 1, 508, 510, 511)

A method of increasing blood plasma half-life of a VWF protein in a subject in need thereof, comprising administering to the subject a composition comprising a monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511.

### Claim 521 (depends on 512, 513, 514, 515, 516, 517, 518, 519, 520)

The method of any one of claims 512-520, wherein the composition is a pharmaceutical composition comprising the monospecific antibody and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 522 (depends on 521)

The method of claim 521, wherein the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of a stabilizer, buffer, surfactant, filler, solvent, tonicity or osmolarity adjusting agent, antioxidant, adjuvant, and antimicrobial agent.

### Claim 523 (depends on 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522)

The method of any one of claims 512-522, wherein the composition or the pharmaceutical composition is administered in combination with one or more additional therapeutic modalities.

### Claim 524 (depends on 523)

The method of claim 523, wherein the one or more additional therapeutic modalities are selected from the group consisting of desmopressin (DDAVP), tranexamic acid (TXA), thalidomide, tamoxifen, ocreotide, a concentrate of plasma-derived VWF protein, a concentrate of VWF protein in complex with FVIII protein, a concentrate of recombinant VWF protein, a concentrate of FVIII protein, hormonal treatment, gene therapy, blood transfusion, platelet transfusion, surgery, and cauterization.

### Claim 525 (depends on 524)

The method of claim 524, wherein the gene therapy is FVIII gene therapy.

### Claim 526 (depends on 523, 524, 525)

The method of any one of claims 523-525, wherein the one or more additional therapeutic modalities are administered to the subject prior to, concurrently with, or subsequent to administration of the composition or the pharmaceutical composition.

### Claim 527 (depends on 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526)

The method of any one of claims 512-526, wherein the subject is a human.

### Claim 528 (depends on 1, 508, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527)

A kit comprising the monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511, and a package insert instructing a user of the kit to perform the method of any one of claims 512-527.

### Claim 529 (depends on 1, 508, 510, 511)

A monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511 for use as a medicament.

### Claim 530 (depends on 529)

The monospecific antibody or the pharmaceutical composition of claim 529 for use in the treatment of a blood disorder characterized by excessive bleeding.

### Claim 531 (depends on 1, 508, 510, 511)

A monospecific antibody of any one of claims 1-508 or the pharmaceutical composition of claim 510 or 511 for use in the treatment of a blood disorder characterized by excessive bleeding.

### Claim 532 (depends on 530, 531)

The monospecific antibody or the pharmaceutical composition for use according to claim 530 or 531, wherein the blood disorder characterized by excessive bleeding is selected from the group consisting of VWD, Heydes syndrome, hemophilia A, disorders of platelet function, and connective tissue disorders.

### Claim 533 (depends on 532)

The monospecific antibody or the pharmaceutical composition for use according to claim 532, wherein the VWD is cVWD or aVWD.

### Claim 534 (depends on 532, 533)

The monospecific antibody or the pharmaceutical composition for use according to claim 532 or 533, wherein the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.
